LOS ANGELES and HOLLISTON, Mass., Nov. 25, 2015 /PRNewswire/ -- Harvard Apparatus Regenerative Technology, Inc. (Nasdaq: HART), a biotechnology company developing bioengineered organ implants for life-threatening conditions, today announced that CEO Jim McGorry will present at the LD Micro "Main Event" investor conference on Tuesday, December 1, 2015 at 2:30 p.m. PT. The presentation will be webcast live and posted for replay (link below) for 30 days. Management will also be available at the conference for one-on-one meetings on Wednesday, December 2, 2015. The conference will be held at the Luxe Sunset Bel Air Hotel in Los Angeles, CA.
Live Webcast/Replay and Presentation Slides: http://wsw.com/webcast/ldmicro9/hart
Jim McGorry will review the company's business strategy and opportunities and comment on HART's recent animal studies that revealed significant results from its second generation (Gen2) bioengineered implant platform for the esophagus, trachea and bronchus, as well as the company's near-term milestones. HART has initiated confirmatory large-animal studies of its Gen2 implants in collaboration with Mayo Clinic. The study design has been completed, prerequisite tests are underway and the Company expects the animal surgeries to occur in December. HART looks to initiate human compassionate use procedures during 2016. Also, the Company plans to file an IND application with the U.S. FDA in 2016, seeking to commence clinical trials for one of HART's three indications.
About LD Micro (www.ldmicro.com)
LD Micro is a (non-registered) investment advisor focused on finding undervalued micro-cap companies. Since 2002 the firm has published reports on select companies, and it also hosts microcap investment conferences such as the LD Micro "Main Event" each December.
About HART: (www.hartregen.com)
Harvard Apparatus Regenerative Technology (HART) makes bioengineered implants for life-threatening conditions. The company's technology platform is to be used to restore function in the esophagus and the trachea and bronchus airways. HART's first generation tracheal implant has been used successfully in five adult human implant procedures approved under compassionate use exemptions, but none of our products are yet approved for marketing by a government regulatory authority. HART is completing further large-animal studies to refine its technology platform with the goal of filing an Investigational New Drug (IND) application with the U.S. Food and Drug Administration in 2016, seeking to initiate clinical trials for one of the company's three indications.
Some of the statements in this press release are "forward-looking" and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These "forward-looking" statements in this press release include, but are not limited to, statements relating to the regulatory approval of any HART products by the FDA, EMA, MHRA or otherwise, which approvals may not be obtained on a timely basis or at all; or success with respect to any collaborations, clinical trials and other development and commercialization efforts of HART products pertaining to the airway or esophagus, which such success may not be achieved or obtained on a timely basis or at all. These statements involve risks and uncertainties that may cause results to differ materially from the statements set forth in this press release, including, among other things, our ability to obtain and maintain regulatory approval for the bioreactors, scaffolds and other devices and product candidates we pursue; the success of our clinical trials and devices; plus other factors described under the heading "Item 1A. Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2014 or described in our other public filings. Our results may also be affected by factors of which we are not currently aware. The forward-looking statements in this press release speak only as of the date of this press release. Harvard Apparatus Regenerative Technology expressly disclaims any obligation or undertaking to release publicly any updates or revisions to such statements to reflect any change in its expectations with regard thereto or any changes in the events, conditions or circumstances on which any such statement is based.
Twitter: Investor Relations @HART_IR_Team
Catalyst Global LLC
David Collins, Tanya Kamatu
SOURCE Harvard Apparatus Regenerative Technology Inc